ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Could PMN be a prime target for acquisition

<< Previous

Bullboard Posts

Next >>

Comment by M101on Apr 20, 2023 3:38pm

86 Views

Post# 35405959

RE:RE:Could PMN be a prime target for acquisition

Not that logic has anything to do with it but, we need cash, they have cash, we're structured to issue many more shares, and we probably have a few dead weight directors that current major shareholders would be willing to replace.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing